ERBB2 and neoplasm: To overcome the limitation of NKG2DL heterogeneity in the tumor, a recent study using a bispecific antibody with two ScFv fragments (linked with a IgG4-Fc) that target Her2 (tumor) and NKG2D (NK cells), respectively, in combination with human NK-92 cells, showed synergistic tumor cell killing effects in both in vitro and in vivo conditions[173].